Yousif Capital Management LLC Trims Stock Position in Vericel Co. (NASDAQ:VCEL)

Yousif Capital Management LLC cut its stake in shares of Vericel Co. (NASDAQ:VCEL) by 1.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,066 shares of the biotechnology company’s stock after selling 234 shares during the period. Yousif Capital Management LLC’s holdings in Vericel were worth $1,047,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP increased its position in shares of Vericel by 214.0% during the third quarter. Wellington Management Group LLP now owns 587,857 shares of the biotechnology company’s stock valued at $24,837,000 after acquiring an additional 400,667 shares during the last quarter. Stifel Financial Corp increased its position in shares of Vericel by 40.0% during the third quarter. Stifel Financial Corp now owns 28,073 shares of the biotechnology company’s stock valued at $1,186,000 after acquiring an additional 8,020 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Vericel by 0.8% during the third quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company’s stock valued at $48,768,000 after acquiring an additional 9,613 shares during the last quarter. Intech Investment Management LLC acquired a new stake in shares of Vericel during the third quarter valued at about $563,000. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its position in shares of Vericel by 4.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,079,048 shares of the biotechnology company’s stock valued at $45,590,000 after acquiring an additional 47,108 shares during the last quarter.

Insider Transactions at Vericel

In other news, insider Jonathan Siegal sold 1,092 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $61.99, for a total transaction of $67,693.08. Following the completion of the sale, the insider now owns 1,206 shares in the company, valued at approximately $74,759.94. The trade was a 47.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert L. Md Zerbe sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $60.00, for a total transaction of $150,000.00. Following the sale, the director now owns 26,595 shares of the company’s stock, valued at $1,595,700. This represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 22,600 shares of company stock worth $1,356,072. 5.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on VCEL. Canaccord Genuity Group lifted their price objective on shares of Vericel from $64.00 to $67.00 and gave the company a “buy” rating in a report on Monday, February 3rd. HC Wainwright restated a “buy” rating and issued a $60.00 price objective on shares of Vericel in a report on Wednesday, January 15th. Truist Financial lifted their price objective on shares of Vericel from $61.00 to $67.00 and gave the company a “buy” rating in a report on Wednesday, December 18th. StockNews.com upgraded shares of Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, December 24th. Finally, Stephens reiterated an “overweight” rating and set a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Vericel presently has an average rating of “Moderate Buy” and an average price target of $63.14.

Vericel Trading Up 0.5 %

Shares of NASDAQ:VCEL opened at $57.09 on Friday. The company has a market capitalization of $2.82 billion, a PE ratio of 951.66 and a beta of 1.72. Vericel Co. has a twelve month low of $39.12 and a twelve month high of $63.00. The firm has a 50 day simple moving average of $57.79 and a 200-day simple moving average of $51.30.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.